MaxCyte IPO Presentation Deck

Reduction in CAR-NK Manufacturing Times Compared to Viral Vectors Preclinical anti-CD19 NK-CAR cells were developed using MaxCyte's GTX system (electroporated mRNA encoding anti-CD19 CAR) and retroviral transduction (anti-CD19-BB-7 construct) methods separately. The results showed transfection efficiency was higher with MaxCyte's GT platform (87% +/- 6%) relative to retroviral transduction (60% +/- 20%) . MaxCyte's GTX system saved roughly 10 days in manufacturing time compared to viral vectors given the more rapid transfection process and fewer days of culture time required. July 2021 ††† ↑ Healthy Donors Expanded NK Cells Expanded NK Cells Retroviral Infection on 2 Consecutive Days -2 Days Anti-CD19 CAR <1 Hour - 24 Hours mRNA Encoding Anti-CD19 CAR with MaxCyte GT 87% + 6 Transfection Efficiency CONFIDENTIAL 8-10 Days Anti-CD19 CAR Customer generated data showed manufacturing time reduction versus viral approaches 60% + 20 Transduction Rate M MaxCyte 34

View entire presentation